Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials

BACKGROUND: Several cancer therapies have been associated with cardiovascular harm in early‐phase clinical trials. However, some cardiovascular harms do not manifest until later‐phase trials. To limit interdisease variability, we focused on breast cancer. Thus, we assessed the reporting of cardiovas...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamid, Arsalan, Anker, Markus S., Ruckdeschel, John C., Khan, Muhammad Shahzeb, Tharwani, Arsal, Oshunbade, Adebamike A., Kipchumba, Rodney K., Thigpen, Samuel C., Anker, Stefan D., Fonarow, Gregg C., Hall, Michael E., Butler, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375478/
https://www.ncbi.nlm.nih.gov/pubmed/35876414
http://dx.doi.org/10.1161/JAHA.121.025206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375478/
https://www.ncbi.nlm.nih.gov/pubmed/35876414
http://dx.doi.org/10.1161/JAHA.121.025206

Ejemplares similares